Table 1.

Pathologic features for specimens used in the study

CaseSizeGrNecpTpNpMF/UStatusCatTsu UsdPMFS (%)PCSS (%)
NAG-12.51NopT1apNxpM055ANEDNAGP9999
NAG-23.62NopTapNxpM052ANEDNAGN, P9999
NAG-33.52NopT1apNxpM041ANEDNAGN, P9999
NAG-42.82NopT1apNxpM045ANEDNAGP9999
NAG-55.82NopT1bpNxpM036ANEDNAGP9595
NAG-64.52NopT1bpNxpM036ANEDNAGP9999
NAG-772NopT1bpN0pM036ANEDNAGP9595
NAG-831NopT1apNxpM011ANEDNAGN, P9999
NAG-971NopT1bpNxpM012ANEDNAGN, P9595
NAG-107.52NopT2pNxpM038ANEDNAGP8488
NAG-114.22NopT1bpNxpM038ANEDNAGP9999
NAG-124.52NopT1bpNxpM036ANEDNAGN, P9999
NAG-132.52NopT1apNxpM036ANEDNAGN, P9999
NAG-142.52NopT1apNxpM06ANEDNAGN, P9999
NAG-153.52NopT1apNxpM032ANEDNAGN, P9999
NAG-162.72NopT1apNxpM029ANEDNAGP9999
NAG-174.53NopT1bpNxpM033ANEDNAGP9999
NAG-1862NopT1bpNxpM034ANEDNAGN, P9595
NAG-192.83NopT1apNxpM033ANEDNAGN, P9999
NAG-2052NopT1bpNxpM026ANEDNAGN, P9995
NAG-2122NopT1apNxpM025ANEDNAGP9999
NAG-224.52NopT1bpNxpM022ANEDNAGP9999
NAG-2331NopT1apNxpM022ANEDNAGP9999
NAG-242.81NopT1apNxpM024ANEDNAGN, P9999
NAG-253.42NopT1apNxpM016ANEDNAGP9999
NAG-261.72NopT1apN0pM019ANEDNAGP9999
AG-183YespT3apNxpM018DODAGN, P
AG-27.53YespT3bpNxpM044AMETAGN, P
AG-393YespT3apN0pM141DODAGP
AG-4153YespT3apN1pM122DODAGP
AG-553NopT3bpN0pM037AMETAGP
AG-683Yesp3apNxpM019DODAGN, P
AG-7104YespT3bpNxpM16DODAGN, P
AG-8112NopT3apN0pM036AMETAGN
AG-97.53NopT3apN0pM03DODAGN, P
AG-1010.33NopT3apNxpM021DODAGN, P
AG-1110.73YespT3apNxpM135AMETAGP, M
AG-12103NopT3bpNxpM019DODAGP
AG-13174YespT3cpNxpM19DODAGN, P
AG-14103YespT3cpN0pM09DODAGN, P
AG-15113YespT3apNxpM130AMETAGP
AG-1611.33NopT3bpN0pM032AMETAGP
AG-1711.83NopT2pN1pM030AMETAGP
AG-188.73YespT3bpNxpM118DODAGN, P
AG-1963NopT3bpNxpM017DODAGN, P
AG-2011.54YespT3apNxpM017AMETAGP
AG-2115.54YespT3apN2pM17DODAGP, M
AG-2214.53YespT3bpN0pM15DODAGM
AG-2313.13YespT3bpN0pM12AMETAGN, P, M
AG-2462NopT1bpNxpM025DODAGN, P
AG-25114YespT4pN2pM19DODAGN, P, M
AG-26NA3NopM112DODAGM
AG-27NA3YespM114AMETAGM
AG-2853Yesp3apN1pM118AMETAGP, M
AG-29NA3YespM118DODAGM
AG-30163YespT3bpN1pM110DODAGP, M
AG-31103NopT2pN1pM112AMETAGN, P
AG-32NA3NopM114AMETAGM
AG-33NA3YespM113AMETAGM
AG-34NA2NopM15AMETAGM
AG-35NA3YespM14AMETAGM
AG-36NA3YespM19AMETAGM
AG-37NA3NopM110AMETAGM
AG-38NA3YespM16AMETAGM
AG-39NA3YespM15AMETAGM
AG-40NA3NopM18AMETAGM
  • NOTE: Tissues used for the microarray experiments are in bold letters.

    Abbreviations: Size, primary tumor size (cm); Gr, nuclear grade; Nec, tumor necrosis; F/U, length of follow-up (mos); Cat, category for study; Tsu Usd, tissue used in the study; PMFS, 5-year predicted metastasis-free survival; PCSS, 5-year predicted cancer-specific survival (based on SSIGN score); ANED, alive with no evidence of disease; DOD, dead of disease; AMET, alive with metastatic disease; NAG, nonaggressive tumor; AG, aggressive tumor; N, nonneoplastic tissue; P, primary tumor; M, metastatic tissue.